APA

Evans C. A., Liu T., Lescarbeau A., Nair S. J., Grenier L., Pradeilles J. A., Glenadel Q., Tibbitts T., Rowley A. M., DiNitto J. P., Brophy E. E., O'Hearn E. L., Ali J. A., Winkler D. G., Goldstein S. I., O'Hearn P., Martin C. M., Hoyt J. G., Soglia J. R., Cheung C., Pink M. M., Proctor J. L., Palombella V. J., Tremblay M. R. & Castro A. C. (20160923). Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. : ACS medicinal chemistry letters.

Chicago

Evans Catherine A, Liu Tao, Lescarbeau André, Nair Somarajan J, Grenier Louis, Pradeilles Johan A, Glenadel Quentin, Tibbitts Thomas, Rowley Ann M, DiNitto Jonathan P, Brophy Erin E, O'Hearn Erin L, Ali Janid A, Winkler David G, Goldstein Stanley I, O'Hearn Patrick, Martin Christian M, Hoyt Jennifer G, Soglia John R, Cheung Culver, Pink Melissa M, Proctor Jennifer L, Palombella Vito J, Tremblay Martin R and Castro Alfredo C. 20160923. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. : ACS medicinal chemistry letters.

Harvard

Evans C. A., Liu T., Lescarbeau A., Nair S. J., Grenier L., Pradeilles J. A., Glenadel Q., Tibbitts T., Rowley A. M., DiNitto J. P., Brophy E. E., O'Hearn E. L., Ali J. A., Winkler D. G., Goldstein S. I., O'Hearn P., Martin C. M., Hoyt J. G., Soglia J. R., Cheung C., Pink M. M., Proctor J. L., Palombella V. J., Tremblay M. R. and Castro A. C. (20160923). Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. : ACS medicinal chemistry letters.

MLA

Evans Catherine A, Liu Tao, Lescarbeau André, Nair Somarajan J, Grenier Louis, Pradeilles Johan A, Glenadel Quentin, Tibbitts Thomas, Rowley Ann M, DiNitto Jonathan P, Brophy Erin E, O'Hearn Erin L, Ali Janid A, Winkler David G, Goldstein Stanley I, O'Hearn Patrick, Martin Christian M, Hoyt Jennifer G, Soglia John R, Cheung Culver, Pink Melissa M, Proctor Jennifer L, Palombella Vito J, Tremblay Martin R and Castro Alfredo C. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. : ACS medicinal chemistry letters. 20160923.